Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-22 15:32 CEST (UTC+2h)

How to demonstrate the bioequivalence of sulodexide [Design Issues]

posted by bjkim97 - Korea / Seoul, 2018-05-30 08:41  - Posting: # 18828
Views: 249

We are planning to development of the sulodexide.

As far as I Know, this product does not have accurate guldelines and design.

So I have reviewed several documents. The FDA and EMEA have identified guidelines for LMWH.

The sulodexide is defined as follows.

Sulodexide is highly purifuled mixture of glycosaminoglycans composed of FMH (Fast Moving Heparin) (80%) and Dermatan sulfate (20%).

I will refer to the FDA enoxaparin recommend guidelines for pharmacodynamic equivalence.

Just one question:
I am not sure if enoxaparin recommendations can be applied to Sulodexide.

I want to hear your opinion. Please give me your opinion

Thanks.

BJ

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,418 posts in 3,912 threads, 1,173 registered users;
online 26 (1 registered, 25 guests [including 6 identified bots]).

The greatest shortcoming of the human race is our inability
to understand the exponential function.    Albert Bartlett

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed